Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 10, 2009

Endo Pays $20M Up Front for Bioniche’s Late-Stage Bladder Cancer Treatment

  • Endo Pharmaceuticals will pay Bioniche Life Sciences an up-front cash fee of $20 million for exclusive rights to the latter’s Phase III bladder cancer treatment, Urocidin. The agreement covers development and marketing in the U.S. with an option for global rights. 

    Bioniche has the potential to receive up to $110 million in additional payments linked to the achievement of future clinical, regulatory, and commercial milestones for Urocidin. In addition, Bioniche will manufacture the product and receive a transfer price for supply.

    “In August Endo plans to launch Valstar™ for the treatment of bladder cancer,” says David Holveck, president and CEO of Endo. “If successful in clinical development, Urocidin has the potential to extend and enhance our recent therapeutic expansion and strengthen the Valstar franchise.”

    Urocidin is a formulation of mycobacterial cell wall-DNA complex (MCC), designed for the treatment of nonmuscle-invasive bladder cancer. It is an intravesical infusion therapy, administered via transurethral catheter into the bladder.     

     



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »